TriSalus Life Sciences Inc (TLSI)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients...
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients...
– Hepatic arterial infusion (HAI) of nelitolimod has been well tolerated and associated with encouraging immunologic activity in patients with HCC and ICC – 4 mg dose demonstrated 3 of 3 patients...
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients...
Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 Reported gross margin of 85% in 1Q24 Secured up to $50 million of debt financing with OrbiMed to support TriNav® Infusion...
– Accomplished industry veteran brings deep strategic and operational expertise TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with...
Call Scheduled for Wednesday, May 15, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to...
$25 million funded at close; up to $25 million of additional capital available at the Company’s option, based on the achievement of certain revenue thresholds Capital from the transaction is...
Reported revenues of $5.7 million in 4Q23, up 77% over prior year Full year revenues of $18.5 million, up 49% over prior year Gross Margin of 90% in 4Q23 and 86% for full year CMS reimbursement...
– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.15 | 2.7027027027 | 5.55 | 5.88 | 5.5 | 7211 | 5.67100433 | CS |
| 4 | -0.09 | -1.55440414508 | 5.79 | 5.915 | 4.84 | 21024 | 5.38094791 | CS |
| 12 | -3.65 | -39.0374331551 | 9.35 | 10.24 | 4.84 | 31632 | 6.91565964 | CS |
| 26 | -3.31 | -36.7369589345 | 9.01 | 10.42 | 4.84 | 35695 | 8.48683851 | CS |
| 52 | -8.1 | -58.6956521739 | 13.8 | 16.24 | 3.32 | 49108 | 7.40342964 | CS |
| 156 | -8.1 | -58.6956521739 | 13.8 | 16.24 | 3.32 | 49108 | 7.40342964 | CS |
| 260 | -8.1 | -58.6956521739 | 13.8 | 16.24 | 3.32 | 49108 | 7.40342964 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
